Showing results (71-80 of 304) with videos related to
Sort By:
Pageof 31
Cancer Treatment Reviews|November 12, 2018
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalationGiacomo Pelizzari, Lorenzo Gerratana, Debora Basile, et al.Gynecologic Oncology|October 4, 2021
Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancersEros Azzalini, Renzo Barbazza, Giorgio Stanta, et al.Journal of Experimental & Clinical Cancer Research : CR|July 17, 2019
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBCMatilde Clarissa Malfatti, Lorenzo Gerratana, Emiliano Dalla, et al.Cancer Treatment Reviews|February 29, 2024
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysisMichele Bartoletti, Marcella Montico, Domenica Lorusso, et al.Cancers|July 26, 2020
"To Anticipate": Neoadjuvant Therapy in Melanoma with a Focus on Predictive BiomarkersMattia Garutti, Silvia Buriolla, Elisa Bertoli, et al.Oncotargets and Therapy|September 14, 2016
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning exampleLorenzo Gerratana, Giovanna De Maglio, Alessandro De Pellegrin, et al.Future Oncology (London, England)|September 13, 2016
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in ItalyFabio Puglisi, Elisa Agostinetto, Lorenzo Gerratana, et al.Recent Patents on Anti-Cancer Drug Discovery|August 1, 2019
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous MelanomaDebora Basile, Camilla Lisanti, Maria A Pizzichetta, et al.Nutrients|December 23, 2023
Nutritional Management of Oncological Symptoms: A Comprehensive ReviewMattia Garutti, Claudia Noto, Brenno Pastò, et al.Future Oncology (London, England)|July 23, 2016
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancerFabio Puglisi, Giancarlo Bisagni, Mariangela Ciccarese, et al.Pageof 31